Cardiovascular Function in Nonclinical Drug Safety Assessment
Authors:
- 28 April 2011
- journal article
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 30 (3) , 272-286
Abstract
There are several recent examples where clinically significant, safety-related, drug effects on hemodynamics or cardiac function were not apparent until large clinical trials were completed or the drugs entered the consumer market. Such late-stage safety issues can have significant impact on patient health and consumer confidence, as well as ramifications for the regulatory, pharmaceutical, and financial communities. This manuscript provides recommendations that evolved from a 2009 HESI workshop on the need for improved translation of nonclinical cardiovascular effects to the clinical arena. The authors conclude that expanded and improved efforts to perform sensitive yet specific evaluations of functional cardiovascular parameters in nonclinical studies will allow pharmaceutical companies to identify suspect drugs early in the discovery and development process while allowing promising drugs to proceed into clinical development.Keywords
This publication has 33 references indexed in Scilit:
- Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysisJournal Of Hypertension, 2009
- Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington DiseaseJournal of Clinical Psychopharmacology, 2009
- Standing on the shoulders of giants: Dean Franklin and his remarkable contributions to physiological measurements in animalsAdvances in Physiology Education, 2009
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Predictive, non-GLP models of secondary pharmacodynamics: putting the best compounds forwardCurrent Opinion in Chemical Biology, 2005
- Origins, practices and future of safety pharmacologyJournal of Pharmacological and Toxicological Methods, 2004
- Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesThe Lancet, 2002
- Safety pharmacology and risk assessmentFundamental & Clinical Pharmacology, 2002
- Chronically Instrumented Conscious Dog Model in Cardiovascular Toxicology StudiesToxicology Mechanisms and Methods, 1993